Treatment of IgA Nephropathy According to Renal Lesions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-20

Study Completion Date

2024-01-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

TIGER study (Treatment of IgA nEphropathy according to Renal lesions) is a prospective openly randomized controlled study.

The main objective is to evaluate the efficacy of early corticotherapy + Renin Angiotensin System (RAS) blockade or inhibitors of Sodium glucose transporter 2 (SGLT2i) (versus RAS blockade or SGLT2i alone) after two years of evolution in IgAN patients with severe histological lesions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis

NCT00885547

IgA Nephropathy

TERMINATED NA

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357

Immunoglobulin A Nephropathy (IgAN)

RECRUITING PHASE3

Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath

NCT01879514

IgA Nephropathy

UNKNOWN NA

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

NCT07305974

IgA Nephropathy (IgAN)

RECRUITING PHASE2

Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.

NCT02187900

IgA Nephropathy

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently, IgAN treatment recommendations are only based on clinico-biological parameters. Steroids therapy appears to have a major role in IgAN treatment, but previous studies evaluating steroids lacked of optimal control group and reproducible evaluation criteria. No prospective study with optimal nephroprotection had included renal pathology in patients selection criteria, although histological evaluation improves patients prognosis prediction. Until now, the lack of a reliable histological classification has precluded the use of histological lesions to evaluate IgAN prognosis and treatment. Given the recently identified major prognostic role of histological lesions in IgAN, we propose to introduce renal pathology to guide the treatment of IgAN in a multicenter study, using currently validated evaluation criteria of chronic kidney disease progression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IgA Nephropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CONTROL

Treatment with Renin Angiotensin system (RAS) blockade or SGLT2i.

Group Type ACTIVE_COMPARATOR

Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)

Intervention Type DRUG

treatment with Renin angiotensin system (RAS) blockade or SGLT2i

EXPERIMENTAL

Corticotherapy + RAS blockade or SGLT2i treatment. Drug injection (intravenous) + tablets

Group Type EXPERIMENTAL

corticotherapy

Intervention Type DRUG

3 IV pulses steroids followed by oral steroids for 4 months

Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)

Intervention Type DRUG

treatment with Renin angiotensin system (RAS) blockade or SGLT2i

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

corticotherapy

3 IV pulses steroids followed by oral steroids for 4 months

Intervention Type DRUG

Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)

treatment with Renin angiotensin system (RAS) blockade or SGLT2i

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \>= 18 years
2. Patient with IgAN
3. Renal biopsy \< 45 days before inclusion visit
4. PCR ratio \>0.75 g/g (within 30 days before or after the renal biopsy)
5. Renal biopsy with at least 8 glomeruli, disclosing at least 2 criteria among:

* mesangial proliferation (according to Oxford criteria)
* endocapillary proliferation (according to Oxford criteria)
* tubulointerstitial fibrosis (according to Oxford criteria) \>25% of the biopsy
* segmental glomerulosclerosis (according to Oxford criteria)
* at least 1 cellular/fibrocellular crescents (C1 according to Oxford criteria)
6. Patient with Social Security Insurance or CMU
7. Patient having signed an informed consent

Exclusion Criteria

1. \>30% increase of serum creatinine after starting nephroprotection therapy (≥ 15 days and ≤ 6 weeks) only for patient under nephroprotection \<45 days of the inclusion visit
2. \>50% cellular/fibrocellular crescents, or \>50% tubulointerstitial fibrosis or \>50% globally sclerotic glomeruli
3. Nephrotic syndrome with minimal change disease and IgA deposits
4. eGFR \<20 ml/min/1,73m2 (CKD-EPI formula) within 30 days before or after the renal biopsy
5. Uncontrolled blood pressure (Systolic blood pressure \>180 mmHg or diastolic blood pressure \> 110 mmHg)
6. Previous corticosteroids treatment (\>20 mg/d during more than 15 days, within the last 3 months before the renal biopsy)
7. Pregnancy or breast feeding or women without sufficient contraception
8. Secondary known forms of IgAN
9. Henoch-Schoenlein purpura
10. Additional other chronic renal disease
11. Contraindication for immunosuppressive therapy, including active intestinal bleeding, active gastric or duodenal ulcer; active infection; any malignancy in a last years before the inclusion; severe psychiatric disease; living vaccines; anti-inflammatory dosages of acetylsalicylic acid
12. Contraindication for RAS orSGLT2i blockade therapy
13. Known allergy or intolerance to corticoids or lactose
14. Organ transplant patient

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No